Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Chronic Obstructive Pulmonary Disease (COPD) and Emphysema in Emergency Medicine Medication

  • Author: Paul Kleinschmidt, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
 
Updated: Jan 27, 2016
 

Medication Summary

Medicines available for ED treatment of chronic obstructive pulmonary disease (COPD) include beta2-adrenoceptor agonists, anticholinergics, oxygen, methylxanthines, corticosteroids, some newer experimental classes of medication, and, possibly magnesium.

  • Terbutaline can be considered for patients with such significant exacerbations that they are not moving enough air to take full advantage of nebulizer therapy.
  • Beta2-adrenoceptor agonists
    • These agents are first-line therapy for COPD, both for acute exacerbations and for acute treatment.[6] Bronchodilators are given on an as-needed basis or on a regular basis to prevent or reduce symptoms.[3] Short-acting agents are usually used for immediate relief of symptoms, whereas long-acting inhaled agents are better for day-to-day mitigation of the disease. The longer-acting agent, indacaterol, is now approved and allows once-daily dosing.[47]
    • Combinations of bronchodilators may improve efficacy and reduce risk of adverse effects rather than increasing the dose of a single agent. Keep in mind that, based on several studies, the acute response to short-acting agents does not predict the future response to long-acting agents.
    • Most of the beta-agonists used are racemic compounds that contain both the R and S enantiomers of the agonist. Much of the pharmacologic activity seems to reside in the R enantiomer, with the S thought to induce the negative side effects. Recently, the R enantiomer of both the short-acting agent albuterol (levalbuterol) and the long-acting agent formoterol (aformoterol) were approved for use in COPD. However, the cost effectiveness of these agents, in light of marginal observed clinical differences, remains controversial and needs further exploration.
    • Although the major action of beta2-agonists is relaxation of airway smooth muscles, they have also been shown to have several other potential effects. They seem to inhibit airway smooth muscle proliferation and inflammatory mediator release, as well as stimulation of mucociliary transport, cytoprotection of the mucosa, and attenuation of neutrophil recruitment and activation.
    • Multiple studies have demonstrated enhanced benefits of action when coadministered with inhaled anticholinergics and with corticosteroids.
    • The greatest single problem that persists in the acute phase is the under dosing of beta-agonists and the nonutilization of anticholinergics. Although only a small subset of patients respond to beta-agonists, a reasonable dose approaches continuous nebulization, as is seen in current asthma treatment.
    • Note that, in mild or moderate exacerbations, the use of MDIs with an aerosol chamber in higher doses (6-12 puffs) can achieve equivalent bronchodilation as the use of a nebulizer. This is particularly important in the office and prehospital setting.
  • Anticholinergics
    • Anticholinergics have an important role in the acute treatment of COPD exacerbations. The anticholinergics reduce airway tone and improve expiratory flow limitation, primarily by blocking parasympathetic activity in the large and medium-sized airways. They also block the release of acetylcholine, which has been linked to increased bronchial smooth muscle tone and mucus hypersecretion.
    • Anticholinergic agents include short-acting agents appropriate for management of acute exacerbations (eg, ipratropium) and long-acting agents (eg, tiotropium, aclidinium, and umeclidinium).
  • Methylxanthines: These agents (eg, theophylline) increase collateral ventilation, respiratory muscle function, mucociliary clearance, and central respiratory drive. Despite this, many questions exist as to their true efficacy, and they have no real role in the acute exacerbation of COPD, except to increase the risk of adverse effects. [7]
  • Phosphodiesterase-4 (PDE-4) inhibitors: Selective PDE-4 inhibitors increase intracellular cyclic adenosine monophosphate (cAMP) and result in bronchodilation. Additionally, they may improve diaphragm muscle contractility and stimulate the respiratory center. Theophylline is a nonspecific phosphodiesterase inhibitor and is now limited to use as an adjunctive agent.
  • Antibiotics
    • These patients are almost uniformly heavily colonized with Haemophilus influenzae, streptococcal pneumonia, and others;[2] however, researchers have not proven these organisms to be the cause of the exacerbation. In fact, viruses are thought to be the instigating factor in as many as half of the cases.
    • The particular antibiotic chosen seems to have much less effect on outcome than the particular host factors of the patient in some studies, with other studies suggesting fluoroquinolones are the best strategy. This may really be a factor of the severity of the exacerbation and whether antibiotics are really indicated for minor exacerbations.[8] However, in a retrospective study of 84,621 hospitalized patients, improved outcomes were seen for all patients with COPD with early antibiotic treatment regardless of disease severity.[9]
    • If antibiotics are given, the choice should provide coverage against pneumococcus, H influenzae,Legionella species, and gram-negative enterics.
    • Daniels et al conducted a randomized, placebo-controlled trial that compared the addition of doxycycline to corticosteroids on clinical outcome in patients hospitalized with acute exacerbation of COPD (n=223).[10] In addition to clinical outcome, other parameters were measured, including microbiological outcome, lung function, and systemic inflammation. The 223 patients enrolled in the study represented 265 COPD exacerbations. In addition to systemic corticosteroids, patients received either doxycycline 200 mg or placebo for 7 days. Results at 30 days were similar between the 2 groups. At 10 days, the doxycycline group showed superiority for clinical success compared with placebo in the intention-to-treat arm but not in the per-protocol arm. Also at day 10, doxycycline was superior for clinical cure, microbiological outcome, use of open label antibiotics, and symptoms.
  • Magnesium: Though controversial, administration of magnesium is thought to produce bronchodilation through the counteraction of calcium-mediated smooth muscle constriction. The addition of intravenous magnesium is now considered to have class B evidence supporting its use in difficult and life-threatening exacerbations.
  • Heliox: Because of helium's low density, some class B evidence now exists for its use as the medium to drive nebulizer therapy. In theory, a mixture of helium and oxygen could improve gas exchange in patients who have an airway obstruction. In the realm of COPD exacerbations, however, the evidence is more slight, and more investigation is needed.
  • Leukotriene receptor antagonists: Intravenous leukotriene receptor antagonists have been shown to have benefit in asthma in limited studies, but, at this time, they have no role in COPD exacerbations.
Next

Bronchodilators

Class Summary

These agents act to decrease muscle tone in both small and large airways in the lungs, thus increasing ventilation. Category includes subcutaneous medications, beta-adrenergic agonists, methylxanthines, and anticholinergics. Note that only 10-15% of all patients with COPD have a true reversible (ie, bronchospastic) component; however, because predicting response is impossible on presentation, all patients should be treated with aggressive bronchodilator therapy.

Terbutaline (Brethaire, Bricanyl)

 

Acts directly on beta2-receptors to relax bronchial smooth muscle, relieving bronchospasm and reducing airway resistance.

Albuterol (Proventil)

 

Beta-agonist useful in treatment of bronchospasm. Drug selectively stimulates beta2-adrenergic receptors of lungs. Bronchodilation results from relaxation of bronchial smooth muscle, which relieves bronchospasm and reduces airway resistance. Note that prior use of long-acting agents, such as salmeterol, does not seem to compromise response to albuterol during acute attacks.

Use 5 mg/mL solution for nebulization; usually underdosed in acute settings. Many studies have demonstrated that high-dose therapy is most efficacious. Goal is continuous therapy in initial treatment phase. Note that properly used MDI with spacer is equal in effectiveness to nebulized therapy.

Theophylline (Theo-Dur, Slo-bid, Theo-24)

 

Acts to increase collateral ventilation, respiratory muscle function, mucociliary clearance, and central respiratory drive. Acts partly by inhibiting phosphodiesterase, elevating cellular cyclic AMP levels, or antagonizing adenosine receptors in bronchi, resulting in relaxation of smooth muscle.

However, clinical efficacy is controversial, especially in acute setting. Author advocates this medicine only if patient was taking medicine already and had subtherapeutic level. Do not give IV form (aminophylline) because it can precipitate arrhythmias, especially in patients such as these who are already in an excess catecholamine state. Measure serum level to adjust dose.

Note that most recent meta-analyses and other literature have failed to show a benefit from the use of methylxanthines in acute exacerbations.

Ipratropium bromide (Atrovent)

 

Dose can (and should) be mixed with first beta-agonist nebulizer because it can take up to 20 min to begin having effect. Admitted controversy exists regarding efficacy of ipratropium, but it still should be part of total treatment picture. Available as nebulized solution and metered-dose inhaler.

Anticholinergic medication that appears to inhibit vagally mediated reflexes by antagonizing action of acetylcholine specifically with muscarinic receptor on bronchial smooth muscle. Vagal tone can be increased by as much as 50% in patients with COPD, so this can have a profound effect.

Albuterol/ipratropium (Combivent Respimat)

 

Ipratropium is chemically related to atropine. It elicits antisecretory properties and, when applied locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa.

Albuterol is a beta2-agonist for bronchospasm refractory to epinephrine. It relaxes bronchial smooth muscle by action on beta2-receptors with little effect on cardiac muscle contractility.

Tiotropium (Spiriva)

 

Not a rescue inhaler. Indicated as maintenance treatment for COPD. A long-acting, once daily quaternary ammonium compound. Elicits anticholinergic/antimuscarinic effects with inhibitory effects on M3 receptors on airway smooth muscles, leading to bronchodilation. Available as a capsule dosage form containing a dry powder for oral inhalation via the HandiHaler inhalation device. Helps patients with COPD by dilating narrowed airways and keeping them open for 24 h.

Aclidinium (Tudorza Pressair)

 

Not a rescue inhaler. Aclidinium is a twice-daily, long-acting selective muscarinic (M3) antagonist (anticholinergic) indicated for long-term maintenance of COPD including bronchitis and emphysema. It is available as breath-activated, dry powder metered-dose inhaler.

Salmeterol (Serevent Diskus)

 

Not a rescue inhaler. Indicated as maintenance treatment for COPD. A long-acting beta2-agonist. By relaxing the smooth muscles of the bronchioles in conditions associated with bronchitis, emphysema, asthma, or bronchiectasis, salmeterol can relieve bronchospasms. Effect also may facilitate expectoration.

Shown to improve symptoms and morning peak flows. May be useful when bronchodilators are used frequently. More studies are needed to establish the role for these agents.

When administered at high or more frequent doses than recommended, incidence of adverse effects is higher. The bronchodilating effect lasts >12 h. Used on a fixed schedule in addition to regular use of anticholinergic agents.

Indacaterol, inhaled (Arcapta Neohaler)

 

Not a rescue inhaler. A long-acting beta2-agonist (LABA) indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. LABAs act locally in the lungs as bronchodilators. Stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP; increased cyclic AMP levels cause relaxation of bronchial smooth muscle. Not for use as initial therapy in patients with acute deteriorating COPD.

Umeclidinium bromide/vilanterol inhaled (Anoro Ellipta)

 

Umeclidinium bromide and vilanterol is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) inhalation powder. It is the first once-daily dual bronchodilator approved. It is indicated for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Indacaterol, inhaled/glycopyrrolate inhaled (Utibron Neohaler)

 

Contains glycopyrronium, which is a long-acting muscarinic antagonist (LAMA) that produces bronchodilation by inhibiting acetylcholine’s effect on muscarinic receptor in the airway smooth muscle. Also contains indacaterol, a long-acting beta2-agonist (LABA) that stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP, and thereby relaxes bronchial smooth muscle. It is indicated for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Glycopyrrolate inhaled (Seebri Neohaler)

 

Contains glycopyrronium, which is a long-acting muscarinic antagonist (LAMA) that produces bronchodilation by inhibiting acetylcholine’s effect on muscarinic receptor in the airway smooth muscle. It is indicated for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Previous
Next

Corticosteroids

Class Summary

These agents have been shown to be effective in accelerating recovery from acute COPD exacerbations. Although they may not make a clinical difference in the ED, they have some effect by 6-8 h into therapy; therefore, early dosing is critical.

Some newer studies are suggesting that inhaled corticosteroids (eg, nebulized budesonide) may be equally effective as IV or PO steroids in the mild-to-moderate exacerbation. In addition, level B evidence suggests that the addition of inhaled corticosteroids to oral agents at discharge may be very beneficial.

Methylprednisolone (Solu-Medrol, Medrol)

 

Usually given in IV form in ED for initiation of corticosteroid therapy, although PO form theoretically equally efficacious. Two forms equal in potency, time of onset, and adverse effects. Inhaled corticosteroids probably equally efficacious and have fewer adverse effects for patients discharged from ED.

Previous
Next

Phosphodiesterase-4 Inhibitors

Class Summary

Selective phosphodiesterase-4 (PDE-4) inhibitors reduce exacerbations, improve dyspnea, and increase lung function in patients with severe COPD.

Roflumilast (Daliresp)

 

Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor. The specific mechanism of action is not well defined but is thought to be related to the effects of increased intracellular cyclic AMP in lung cells. It is indicated to decrease the frequency of exacerbations or the worsening of symptoms from severe COPD.

Previous
Next

Electrolyte supplements

Class Summary

Magnesium is used to replenish stores that become depleted in periods of adrenergic excess such as asthma attacks, COPD exacerbations, and diuretic use.

Magnesium sulfate

 

Thought to produce bronchodilation through counteraction of calcium-mediated smooth muscle constriction. Again, for every study showing positive finding, probably another shows no benefit, but given properly, magnesium is safe and may have some benefit.

Previous
 
 
Contributor Information and Disclosures
Author

Paul Kleinschmidt, MD Consulting Staff, Department of Emergency Medicine, Womack Army Medical Center

Paul Kleinschmidt, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Received ownership interest from ScrubCast, INC for other.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Paul Blackburn, DO, FACOEP, FACEP Attending Physician, Department of Emergency Medicine, Maricopa Medical Center

Paul Blackburn, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, Arizona Medical Association, American College of Osteopathic Emergency Physicians, American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director for Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, Society for Academic Emergency Medicine, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians

Disclosure: Nothing to disclose.

References
  1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16. 363(12):1128-38. [Medline].

  2. Siddiqi A, Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2008. 3(1):31-44. [Medline]. [Full Text].

  3. [Guideline] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2008. [Full Text].

  4. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010 Oct 18. 341:c5462. [Medline]. [Full Text].

  5. Pierson DJ. Indications for mechanical ventilation in adults with acute respiratory failure. Respir Care. 2002 Mar. 47(3):249-62; discussion 262-5. [Medline].

  6. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc. 2007 Oct 1. 4(7):526-34. [Medline].

  7. Barr RG, Rowe BH, Camargo CA Jr. Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001. (1):CD002168. [Medline].

  8. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007. 8:30. [Medline].

  9. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010 May 26. 303(20):2035-42. [Medline].

  10. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Jan 15. 181(2):150-7. [Medline].

  11. Balter M, Weiss K. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?. Can Fam Physician. 2006 Oct. 52(10):1236-42. [Medline].

  12. [Guideline] Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003 Jul-Aug. 10 Suppl B:3B-32B. [Medline].

  13. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003 Jun 26. 348(26):2618-25. [Medline].

  14. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000 Sep. 36(3):191-7. [Medline].

  15. Baigorri F, Joseph D, Artigas A, Blanch L. Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease. Crit Care Med. 1999 Oct. 27(10):2153-8. [Medline].

  16. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007 Oct 1. 4(7):512-21. [Medline].

  17. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1995 Apr. 25(4):470-3. [Medline].

  18. Dailey RH. Chronic obstructive pulmonary disease. Rosen P, et al, eds. Emergency Medicine Concepts and Clinical Practice. 3rd ed. Mosby-Year Book Inc; 1992. 1093-1111.

  19. de Palo VA. Pulmonary disease: pneumonia, chronic obstructive pulmonary disease, asthma, and thromboembolic disease. J Am Podiatr Med Assoc. 2004 Mar-Apr. 94(2):157-67. [Medline].

  20. Dewan NA, Daniels A, Zieman G, Kramer T. The National Outcomes Management Project: a benchmarking collaborative. J Behav Health Serv Res. 2000 Nov. 27(4):431-6. [Medline].

  21. Faulkner MA, Hilleman DE. Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy. 2003 Oct. 23(10):1300-15. [Medline].

  22. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 1993 Apr 8. 328(14):1017-22. [Medline].

  23. FitzGerald JM, Shragge D, Haddon J, Jennings B, Lee J, Bai T, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000 Jan-Feb. 7(1):61-7. [Medline].

  24. Fromm RE Jr, Varon J. Acute exacerbations of obstructive lung disease. What to do when immediate care is crucial. Postgrad Med. 1994 Jun. 95(8):101-6. [Medline].

  25. Greenfield RH. Pulmonary disease in the elderly. Lecture presented at the ACEP Scientific Assembly. 1994.

  26. Hirschmann JV. Do bacteria cause exacerbations of COPD?. Chest. 2000 Jul. 118(1):193-203. [Medline].

  27. Hirshberg AJ, Dupper RL. Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia. Ann Emerg Med. 1994 Oct. 24(4):701-3. [Medline].

  28. Ingram RH. Harrison's Principles of Internal Medicine. Fauci AS, et al, eds. Chronic bronchitis, emphysema, and airway obstruction. McGraw-Hill Companies: 1991. 1074-1082.

  29. Jaber S, Fodil R, Carlucci A, Boussarsar M, Pigeot J, Lemaire F, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Apr. 161(4 Pt 1):1191-200. [Medline].

  30. Kino RJ. The difficult COPD patient: Alternative therapy regimens. Lecture presented at the ACEP Scientific Assembly. 1996.

  31. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER Jr. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med. 1999 Sep. 107(3):209-13. [Medline].

  32. Lieberman D, Lieberman D, Ben-Yaakov M, Lazarovich Z, Hoffman S, Ohana B, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001 Jul. 40(3):95-102. [Medline].

  33. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002 Mar 1. 165(5):698-703. [Medline].

  34. Peng CC, Aspinall SL, Good CB, Atwood CW Jr, Chang CC. Equal effectiveness of older traditional antibiotics and newer broad-spectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis. South Med J. 2003 Oct. 96(10):986-91. [Medline].

  35. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995 Mar 22-29. 273(12):957-60. [Medline].

  36. Schmidt GA, Hall JB. Acute or chronic respiratory failure. Assessment and management of patients with COPD in the emergency setting. JAMA. 1989 Jun 16. 261(23):3444-53. [Medline].

  37. Sclar DA, Legg RF, Skaer TL, Robison LM, Nemic NL. Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther. 1994 May-Jun. 16(3):595-601; discussion 594. [Medline].

  38. Siedman JC. Chronic obstructive pulmonary disease. Tintinalli J, et al, eds. Emergency Medicine: A Comprehensive Study Guide. McGraw-Hill Co; 1992. 298-302.

  39. Skorodin MS. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Current thinking, practices, and controversies. Arch Intern Med. 1993 Apr 12. 153(7):814-28. [Medline].

  40. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 1995 Mar 13. 155(5):496-500. [Medline].

  41. Sohy C, Pilette C, Niederman MS, Sibille Y. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed?. Eur Respir J. 2002 May. 19(5):966-75. [Medline].

  42. Stewart AG, Waterhouse JC, Billings CG, Baylis P, Howard P. Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic chronic obstructive pulmonary disease. Thorax. 1994 Oct. 49(10):995-8. [Medline].

  43. US Department of Health and Human Services, National Institutes of Health, Third Expert Panel on the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute National Asthma Education and Prevention Program. US Department of Health and Human Services. August 28, 2007.

  44. Varkey B. Obstructive, occupational, and environmental diseases. Curr Opin Pulm Med. 2004 Mar. 10(2):97. [Medline].

  45. [Guideline] Whittle A. COPD guidelines. Thorax. 1999 Apr. 54(4):375-6. [Medline].

  46. Zehner WJ Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. Acad Emerg Med. 1995 Aug. 2(8):686-91. [Medline].

  47. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term Safety and Efficacy of Indacaterol, a Long-Acting {beta}2-Agonist, in Subjects With COPD: A Randomized, Placebo-Controlled Study. Chest. 2011 Jul. 140(1):68-75. [Medline].

 
Previous
Next
 
Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells.
Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells (high-powered view).
Posteroanterior (PA) and lateral chest radiograph in a patient with severe chronic obstructive pulmonary disease (COPD). Hyperinflation, depressed diaphragms, increased retrosternal space, and hypovascularity of lung parenchyma is demonstrated.
Chronic obstructive pulmonary disease (COPD). A lung with emphysema shows increased anteroposterior (AP) diameter, increased retrosternal airspace, and flattened diaphragms on lateral chest radiograph.
Chronic obstructive pulmonary disease (COPD). A lung with emphysema shows increased anteroposterior (AP) diameter, increased retrosternal airspace, and flattened diaphragms on posteroanterior chest radiograph.
Subcutaneous emphysema and pneumothorax.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.